|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5524393||1401416||2017||3 صفحه PDF||سفارش دهید||دانلود کنید|
- HSCT-TMA maybe related to complement dysregulation.
- Genetic complement dysregulation in HSCT may be acquired from the donor.
- The screening of donors for genetic complement dysregulation may be useful in HSCT.
Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) is a severe complication whose pathophysiology is unknown. We describe 6 patients in which the disease was associated with complement regulatory gene abnormalities received from their respective donors. It is suggested that mutated and transplanted monocyte-derived cells are responsible for production of abnormal proteins, complement dysregulation, and, ultimately, for the disease. This observation might have important drawbacks as far as HSCT-TMA pathophysiology and treatment are concerned.
Journal: Biology of Blood and Marrow Transplantation - Volume 23, Issue 9, September 2017, Pages 1580-1582